Skip to main content
. 2022 May 25;8(6):e09538. doi: 10.1016/j.heliyon.2022.e09538

Figure 2.

Figure 2

The survival curves of all patients with HBV-related advanced hepatocellular carcinoma treated with lenvatinib plus sintilimab and with lenvatinib alone. Cumulative progression-free survival curves, in which the blue lines show the patients in the combined therapy group and the red lines show the patients in the lenvatinib monotherapy group.